CHICAGO — Late-stage outcomes of Novo Nordisk’s weight problems candidate CagriSema counsel the drug is akin to Eli Lilly’s Zepbound on security and efficacy, additional information indicating that CagriSema might not be the standout therapy that buyers had hoped for.
Novo beforehand reported that sufferers on CagriSema misplaced 20% of their weight in a 68-week Section 3 trial when taking a look at all contributors, the same degree of weight reduction seen in Zepbound research.
Novo is planning an extended CagriSema research to see if sufferers can proceed to lose extra weight, however full outcomes launched Sunday present that the speed of weight reduction began to plateau on the finish of 68 weeks, elevating questions round how way more weight sufferers would be capable to lose.
This text is unique to STAT+ subscribers
Unlock this text — plus each day protection and evaluation of the pharma business — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
